Biologic therapies have transformed the treatment of inflammatory bowel disease. Many gastroenterology practices now run infusion suites where patients with Crohn's disease and ulcerative colitis receive regular treatments. For practices, this service line can be a valuable source of revenue and an important part of patient care. It is also one of the most financially risky areas to manage.

Biologic drugs are expensive, payer rules are strict, and billing requirements are detailed. A single error in drug coding, units, or authorization can lead to a denied claim worth thousands of dollars. This article explains how infusion billing works, where practices run into trouble, and how professional billing support helps protect this high-value service.

Note: Drug coverage, codes, and payer policies change frequently. Always confirm current requirements with each payer.

Why Infusion Billing Is High Risk

Several factors make infusion billing different from routine office billing.

• High drug costs. One infusion may cost thousands of dollars, so a denial has a major impact on cash flow.
• The practice often purchases the drug up front. In a buy-and-bill model, the practice pays for the medication and must be reimbursed later. If the claim is denied, the practice absorbs the loss.
• Complex coding. Each infusion involves a drug code, units, administration codes, and often supporting diagnosis codes and modifiers.
• Strict payer controls. Prior authorization, step therapy, and site-of-care rules are common.
• Frequent policy changes. Biosimilars, new drug approvals, and updated medical policies change coverage regularly.
• Documentation demands. Dose, lot numbers, administration times, and medical necessity must all be recorded accurately.

Because of this risk, practices that offer infusion services need more than basic billing. They need a process built for specialty drug claims.

How Medical Billing Services Support Infusion Practices

Specialized medical billing services take responsibility for the details that make or break infusion claims: verifying benefits, securing authorizations, coding drugs and administration correctly, submitting clean claims, and following up on denials. Instead of leaving these tasks to a busy front desk, practices can rely on trained staff who understand drug billing rules and payer behavior.

Practice Revenue Partners helps practices manage the full infusion lifecycle, from the first benefit check to final payment. By catching authorization gaps, unit errors, and documentation problems before claims go out, the goal is to protect the practice from large, avoidable write-offs. Reporting also shows which drugs, payers, and locations generate the most denials, so leaders can make decisions based on data.

Buy-and-Bill vs. Specialty Pharmacy

Practices generally obtain biologic drugs in one of two ways, and each has billing implications.

Buy-and-bill. The practice purchases the drug, stores it, administers it, and bills the payer under the medical benefit. This can bring revenue through drug reimbursement and administration fees, but it also requires upfront capital, inventory management, and careful claim submission.

Specialty pharmacy (white bagging or brown bagging). The payer requires the drug to be supplied by a specialty pharmacy under the pharmacy benefit. The practice may bill only for administration. This reduces financial risk but changes revenue and requires coordination with the pharmacy on delivery and timing.

Some payers mandate one model, while others allow either. Knowing which pathway applies to each patient is an essential first step, since billing the wrong benefit leads to denials.

Key Billing Elements for IBD Infusions

Every infusion claim contains several parts. Getting each one right is critical.

Drug codes (HCPCS J-codes and Q-codes). Biologics are reported with specific codes, and each code is tied to a defined unit of measure. For example, infliximab products are reported in units based on a set number of milligrams, while other drugs use different units. Biosimilars have their own codes. Reporting the wrong code or the wrong number of units is one of the most common and costly errors.

Administration codes. Infusion administration is reported with CPT codes such as 96365 for an initial intravenous infusion and 96366 for each additional hour, among others. Time documentation must support the codes billed.

National Drug Codes (NDC). Many payers require the NDC, along with quantity and unit of measure, on the claim. Missing or incorrect NDC information leads to rejections.

Diagnosis codes. Diagnoses for conditions such as Crohn's disease and ulcerative colitis must support medical necessity and match payer policy.

Modifiers. Drug waste modifiers may be required. Medicare, for example, requires JW or JZ on claims for certain single-dose drugs to report discarded drug or the absence of waste. Other modifiers may apply for specific payer rules.

Place of service. The location where the infusion is given affects payment and may be restricted by payer site-of-care policies.

Each of these elements must agree with the authorization and the documentation in the chart.

Prior Authorization and Step Therapy

Almost every payer reviews biologic drugs before approving them. Common requirements include:

• Documentation of diagnosis and disease severity
• Records of previous treatments and their outcomes
• Evidence that cheaper or preferred drugs were tried first, known as step therapy
• Dosing schedules and expected duration of treatment
• Periodic re-authorization after a set number of months

Authorizations often specify the drug, dose, number of units, dates, and sometimes the site of care. If a patient's dose changes, or treatment continues past the approved period, a new approval may be needed. Missing this step is a leading cause of denials. A tracking system that alerts staff before authorizations expire prevents gaps in treatment and gaps in payment.

Connecting Infusion Billing to Gastroenterology Billing Services

Infusion services are part of a broader GI practice, and the strongest results come when they are managed alongside office visits, endoscopy, and other procedures. Experienced gastroenterology billing services understand how infusion claims relate to clinic visits, lab monitoring, and endoscopic evaluations that are often part of an IBD patient's care.

For example, a patient may have an office visit on the same day as an infusion. Whether the visit is billable separately depends on documentation of a significant, separately identifiable service and, in many cases, correct use of modifiers. Billing both without the right support can trigger denials, while missing a legitimate visit leaves revenue uncollected. A billing team that works across the GI service lines can handle these situations consistently.

Coordinated billing also supports better financial analysis. Practices can compare revenue and denial rates across procedures, infusions, and visits, and see whether the infusion program is performing as expected.

Common Biologic Billing Errors

Practices that struggle with infusion revenue often make the same mistakes:

1. Infusing without a valid authorization. The drug is administered, but approval was missing, expired, or did not cover the dose.
2. Incorrect unit conversion. The dose given is not translated correctly into billing units for the drug code.
3. Missing NDC information. The claim lacks the identifier, quantity, or unit of measure the payer requires.
4. Wrong administration codes. Time documentation does not support the infusion codes billed.
5. Billing the wrong benefit. The drug was supplied by a specialty pharmacy, but the practice billed the medical benefit, or the reverse.
6. Ignoring drug waste rules. Required modifiers are omitted, or waste is not documented.
7. Outdated drug codes. A biosimilar or new code takes effect, but the practice continues to use the old one.
8. Inadequate documentation. Missing lot numbers, start and stop times, or clinical notes weaken the claim.
9. No follow-up on underpayments. Reimbursement is lower than expected, but nobody compares payment with the contracted rate.

Protecting Margins in a Buy-and-Bill Model

Because the practice carries the drug cost, small shortfalls matter. To protect margins:

• Verify benefits before ordering the drug. Do not purchase inventory for a patient whose coverage or authorization is uncertain.
• Track acquisition cost against reimbursement. Know which drugs and payers are profitable.
• Monitor inventory and expiration dates to minimize waste.
• Reconcile payments to claims and challenge underpayments.
• Review denials by drug and payer to find patterns.
• Maintain strong documentation for every administration.

Practices should also have a clear policy for what happens if an authorization is denied after a patient's treatment is scheduled, so staff know when to delay or reschedule.

Frequently Asked Questions

1. Why is billing for IBD infusions so difficult?
Because it involves expensive drugs, detailed coding, prior authorizations, unit conversions, and strict documentation requirements, so small mistakes can lead to large denials.

2. What is buy-and-bill?
It is a model where the practice buys the drug, administers it, and then bills the payer, taking on the financial risk if the claim is denied or underpaid.

3. What codes are used for infusion billing?
Claims typically include a drug code (such as a J-code), administration codes (such as 96365 and 96366), diagnosis codes, and sometimes an NDC and modifiers.

4. What are JW and JZ modifiers?
They relate to drug waste reporting. JW indicates discarded drug amounts, and JZ indicates there was no waste. Medicare requires them on claims for certain single-dose drugs.

5. How often do biologic authorizations need renewal?
It depends on the payer and the drug, but many approvals last for a limited period and require re-authorization. Tracking expiration dates is essential.

6. Can a billing company manage both infusion and office-based GI billing?
Yes. Many billing partners handle all GI service lines together, which improves consistency and reporting.

Final Thoughts

Infusion services can be a strong addition to a gastroenterology practice, but they demand careful financial management. With the right authorization process, accurate coding, complete documentation, and persistent follow-up, practices can deliver biologic therapy to patients while protecting their revenue.

If your GI group offers or plans to offer infusion services, Practice Revenue Partners can help you build a billing process that handles the complexity of biologic drug claims and keeps your margins healthy.